8,9-dimethyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-5,6-dihydropyrazolo[3,4-h]quinazolin-2-amine | 1356589-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 8,9-dimethyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-5,6-dihydropyrazolo[3,4-h]quinazolin-2-amine
• CAS: 1356589-01-9
• 化学式: C₂₂H₂₇N₇
• 分子量: 389.503
• InChiKey: DNNORDIFJWPEAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• CDK4/6 INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH THEREOF AND USE THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20210214358A1

  公开（公告）日：2021-07-15

  Provided are a CDK4/6 inhibitor, a pharmaceutically acceptable salt thereof and a polymorph thereof, and the use thereof. In particular, provided are a polymorph of 2-cyclopropyl-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-3-isopropyl-3,8-dihydroimidazo[4′,5′,4,5]cyclopentadieno[1,2-d]pyrimidin-5-amine and a pharmaceutically acceptable salt thereof, and the use thereof. In addition, further disclosed are a pharmaceutical composition of the compound and the use thereof.

  提供了一种CDK4/6抑制剂，其药用盐及其多晶形式，以及其用途。具体提供了2-环丙基-N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-3-异丙基-3,8-二氢咪唑[4′,5′,4,5]环戊二烯[1,2-d]嘧啶-5-胺的多晶形式及其药用盐，以及其用途。此外，还披露了该化合物的药物组合物及其用途。
• AMINOPYRAZOLOQUINAZOLINES
  申请人：Treu Matthias

  公开号：US20120238542A1

  公开（公告）日：2012-09-20

  Compounds of general formula (I) wherein the groups R 1 to R 3 and X are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

  通式（I）中R1至R3和X组的定义如索赔1所述，适用于治疗以细胞过度或异常增殖为特征的疾病，包含此类化合物的药物制剂以及它们作为药物的用途。
• PYRIDINAMINE-SUBSTITUTED HETEROTRICYCLO COMPOUNDS, PREPARATION THEREOF, AND USE IN MEDICINES
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：EP3505519A1

  公开（公告）日：2019-07-03

  The present disclosure relates to pyridinamine-substituted heterotricyclo compounds, a preparation method thereof, and a use thereof in medicines. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method and a use thereof are disclosed, wherein the groups in the formula (I) are as defined in the Description and claims.

  本公开涉及吡啶胺取代的杂环化合物、其制备方法及其在药物中的用途。具体地说，本发明公开了一种式（I）化合物或其药学上可接受的盐、立体异构体、溶液剂或原药，以及其制备方法和用途，其中式（I）中的基团如说明书和权利要求书中所定义。
• Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US11168088B2

  公开（公告）日：2021-11-09

  The present disclosure relates to pyridinamine-substituted heterotricyclo compounds, a preparation method thereof, and a use thereof in medicines. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method and a use thereof are disclosed, wherein the groups in the formula (I) are as defined in the Description and claims.

  本公开涉及吡啶胺取代的杂环化合物、其制备方法及其在药物中的用途。具体地说，本发明公开了一种式（I）化合物或其药学上可接受的盐、立体异构体、溶液剂或原药，以及其制备方法和用途，其中式（I）中的基团如说明书和权利要求书中所定义。
• PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20200039983A1

  公开（公告）日：2020-02-06

  The present disclosure relates to pyridinamine-substituted heterotricyclo compounds, a preparation method thereof, and a use thereof in medicines. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method and a use thereof are disclosed, wherein the groups in the formula (I) are as defined in the Description and claims.